A Phase 2 interventional study of GSK4532990 in Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline. Completed at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 214th largest by enrollment of the 460 interventional ones that give a count, is one of 29 that started in 2024, is one of 192 in phase 2, and was the 497th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 29 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 9 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive GSK4532990 Dose 1
Drug: GSK4532990
Participants will receive GSK4532990 Dose 2
Drug: GSK4532990
Participants will receive GSK4532990 Dose 3
Drug: GSK4532990
Participants will receive GSK4532990 Dose 4
Drug: GSK4532990
GSK4532990 will be administered
Predicted Mean Percent Change From Baseline (CFB) in Liver Biopsy-derived HSD17B13 Protein Expression Levels
Predicted mean percent change from baseline in liver biopsy-derived HSD17B13 protein expression levels quantify the predicted change in HSD17B13 protein expression, calculated as a percentage relative to baseline levels. The predictions are derived from a nonlinear mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) target engagement model. This model utilized HSD17B13 protein concentrations obtained from pre-dose and post-dose liver biopsy samples. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1), At weeks 8, 12 and 28
Predicted Mean Percent Change From Baseline (CFB) in Liver Biopsy-derived HSD17B13 mRNA Expression Levels
Predicted mean percent change from baseline (CFB) in liver biopsy-derived HSD17B13 mRNA expression levels, expressed as a percentage relative to pre-dose baseline quantified the alteration in HSD17B13 mRNA expression at each treatment arm and post-dose biopsy time. The prediction, along with its 95% prediction interval, was estimated using a nonlinear mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) target engagement model. This model leveraged HSD17B13 mRNA concentrations obtained from pre-dose and post-dose liver biopsy samples. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1), At weeks 8, 12 and 28
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Quantifiable Concentration (AUC0-t)
Blood samples were collected for the analysis of pharmacokinetic (PK) parameters.
Time frame: Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours
Maximum Observed Concentration (Cmax)
Blood samples were collected for the analysis of pharmacokinetic (PK) parameters.
Time frame: Pre-dose (Day 1) and at post-dose 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours
Percent Change From Baseline (CFB) in the Observed HSD17B13 Protein Expression Levels
Percent change from baseline in the observed HSD17B13 protein expression levels quantified the change in HSD17B13 protein expression relative to pre-treatment baseline levels, expressed as a percentage. This measure is calculated for each participant with non-missing baseline and post-dose liver biopsies. Percent change in data is summarized. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1), At weeks 8, 12 and 28
Percent Change From Baseline (CFB) in the Observed HSD17B13 mRNA Expression Levels
Percent change from baseline (CFB) in the observed HSD17B13 mRNA expression levels, expressed as a percentage relative to pre-treatment baseline levels quantified the change in HSD17B13 mRNA expression. This measure is calculated for each participant with non-missing baseline and post-dose liver biopsies. Percent change in data is summarized. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1), At weeks 8, 12 and 28
| Milestone | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| Started | 17 | 15 | 15 | 14 |
| Safety population | 17 | 15 | 15 | 14 |
| Hsd17b13 mrna concentration population | 10 | 13 | 9 | 13 |
| Hsd17b13 protein concentration population | 10 | 11 | 9 | 10 |
| Pharmacokinetic population | 17 | 15 | 15 | 14 |
| Completed | 17 | 15 | 14 | 14 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
Predicted mean percent change from baseline in liver biopsy-derived HSD17B13 protein expression levels quantify the predicted change in HSD17B13 protein expression, calculated as a percentage relative to baseline levels. The predictions are derived from a nonlinear mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) target engagement model. This model utilized HSD17B13 protein concentrations obtained from pre-dose and post-dose liver biopsy samples. Baseline value was defined as the pre-dose value on Day 1.
| Percent Change | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| CFB to Week 8 | -57.27 (-64.27 to -50.00) | -83.16 (-87.16 to -75.47) | -86.76 (-90.13 to -79.78) | -88.79 (-91.71 to -82.12) |
| CFB to Week 12 | -49.03 (-55.55 to -42.73) | -80.21 (-83.96 to -75.64) | -84.94 (-87.93 to -81.06) | -87.64 (-90.16 to -83.98) |
| CFB to Week 28 | -26.82 (-34.44 to -18.69) | -61.82 (-70.08 to -51.31) | -70.02 (-76.94 to -60.66) | -75.27 (-81.16 to -66.83) |
Predicted mean percent change from baseline (CFB) in liver biopsy-derived HSD17B13 mRNA expression levels, expressed as a percentage relative to pre-dose baseline quantified the alteration in HSD17B13 mRNA expression at each treatment arm and post-dose biopsy time. The prediction, along with its 95% prediction interval, was estimated using a nonlinear mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) target engagement model. This model leveraged HSD17B13 mRNA concentrations obtained from pre-dose and post-dose liver biopsy samples. Baseline value was defined as the pre-dose value on Day 1.
| Percent Change | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| CFB to Week 8 | -57.85 (-66.28 to -49.38) | -87.60 (-91.39 to -80.47) | -91.10 (-93.98 to -86.16) | -92.95 (-95.30 to -89.19) |
| CFB to Week 12 | -49.98 (-56.74 to -43.04) | -84.50 (-88.03 to -80.01) | -89.07 (-91.74 to -85.56) | -91.54 (-93.69 to -88.62) |
| CFB to Week 28 | -28.55 (-37.34 to -19.28) | -67.07 (-75.63 to -55.61) | -75.45 (-82.32 to -65.35) | -80.59 (-86.22 to -71.73) |
Blood samples were collected for the analysis of pharmacokinetic (PK) parameters.
| hours*nanograms per milliter(h*ng/mL) | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Quantifiable Concentration (AUC0-t) | 518 ± 65.4 | 6530 ± 33.9 | 14800 ± 44.3 | 46400 ± 38.8 |
Blood samples were collected for the analysis of pharmacokinetic (PK) parameters.
| ng/mL | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 43.6 ± 46.3 | 412 ± 51.0 | 914 ± 61.3 | 2890 ± 60.2 |
Percent change from baseline in the observed HSD17B13 protein expression levels quantified the change in HSD17B13 protein expression relative to pre-treatment baseline levels, expressed as a percentage. This measure is calculated for each participant with non-missing baseline and post-dose liver biopsies. Percent change in data is summarized. Baseline value was defined as the pre-dose value on Day 1.
| Percent change | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| CFB to Week 8 | -57.47 (-68.47 to -46.47) | -91.61 (-102.81 to -80.41) | -82.20 (-94.69 to -69.71) | -86.96 (-99.81 to -74.10) |
| CFB to Week 12 | -43.37 (-54.55 to -32.20) | -81.78 (-91.75 to -71.81) | -86.14 (-97.20 to -75.07) | — |
| CFB to Week 28 | — | — | — | -69.97 (-79.02 to -60.92) |
Percent change from baseline (CFB) in the observed HSD17B13 mRNA expression levels, expressed as a percentage relative to pre-treatment baseline levels quantified the change in HSD17B13 mRNA expression. This measure is calculated for each participant with non-missing baseline and post-dose liver biopsies. Percent change in data is summarized. Baseline value was defined as the pre-dose value on Day 1.
| Percent change | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| CFB to Week 8 | -72.63 (-82.04 to -63.22) | -91.83 (-101.65 to -82.02) | -91.66 (-102.36 to -80.96) | -90.16 (-98.13 to -82.19) |
| CFB to Week 12 | -52.18 (-61.49 to -42.87) | -88.14 (-95.54 to -80.73) | -91.40 (-100.83 to -81.97) | — |
| CFB to Week 28 | — | — | — | -80.74 (-89.39 to -72.09) |
Collected over All cause mortality, Non-Serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs) were collected upto approximately 87 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK4532990 25 Milligram (mg) | 0/17 (0%) | 1/17 (5.9%) | 8/17 (47.1%) |
| GSK4532990 200 mg | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| GSK4532990 400 mg | 0/15 (0%) | 1/15 (6.7%) | 5/15 (33.3%) |
| GSK4532990 800 mg | 0/14 (0%) | 0/14 (0%) | 8/14 (57.1%) |
| Event | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| Hepatic enzyme increasedInvestigations | 0/17 | 0/15 | 1/15 | 0/14 |
| Chest painGeneral disorders | 1/17 | 0/15 | 0/15 | 0/14 |
| Scrotal cellulitisInfections and infestations | 1/17 | 0/15 | 0/15 | 0/14 |
| Event | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg |
|---|---|---|---|---|
| SinusitisInfections and infestations | 0/17 | 0/15 | 0/15 | 2/14 |
| Upper respiratory tract infectionInfections and infestations | 2/17 | 0/15 | 0/15 | 1/14 |
| NauseaGastrointestinal disorders | 0/17 | 0/15 | 0/15 | 1/14 |
| AstheniaGeneral disorders | 0/17 | 0/15 | 0/15 | 1/14 |
| Injection site haemorrhageGeneral disorders | 0/17 | 0/15 | 0/15 | 1/14 |
| Injection site rashGeneral disorders | 0/17 | 0/15 | 0/15 | 1/14 |
| Injection site reactionGeneral disorders | 0/17 | 0/15 | 0/15 | 1/14 |
| Subcapsular hepatic haematomaHepatobiliary disorders | 0/17 | 0/15 | 0/15 | 1/14 |
| Chronic sinusitisInfections and infestations | 0/17 | 0/15 | 0/15 | 1/14 |
| Infected cystInfections and infestations | 0/17 | 0/15 | 0/15 | 1/14 |
| Age, Continuous(YEARS) | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg | Total |
|---|---|---|---|---|---|
| Mean | 50.8 ± 10.11 | 51.9 ± 9.68 | 50.7 ± 11.04 | 55.4 ± 11.13 | 52.1 ± 10.39 |
| Sex: Female, Male(Participants) | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg | Total |
|---|---|---|---|---|---|
| Female | 12 | 10 | 9 | 9 | 40 |
| Male | 5 | 5 | 6 | 5 | 21 |
| Race/Ethnicity, Customized(Participants) | GSK4532990 25 Milligram (mg) | GSK4532990 200 mg | GSK4532990 400 mg | GSK4532990 800 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 16 | 13 | 15 | 13 | 57 |
| Unknown | 1 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Jan 2024 to primary completion in Sep 2025, 20 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 20 months is close to that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK4532990
Non-alcoholic Fatty Liver Disease →